CD86 and colitis: In contrast, AMD3100 blocked the therapeutic function of ERCs, and much more cells of CD11c+MHCII+, CD11c+CD86+, and CD11c+CD40+ DCs were found in colitis mice treated with AMD3100-pretreated ERCs, which were indistinguishable from that of the untreated group (Fig. 4).